Legend Biotech Corp (LEGN) income statement
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.25+0.14 (+0.87%)
Close on Nov 18, 2026Market cap $3.01BP/E –Yield –
Legend Biotech Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 57.2%
- Operating margin
- -4.3%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 3.04
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 166.7%
Valuation
- P/E ratio
- –
- Price to sales
- 2.36
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?